• • LINC00114 and HNRNPA1 are significantly overexpressed in CRC tissues and cells, with positive correlation to CD31 (p < 0.01), indicating their potential as biomarkers for metastatic CRC and anti-angiogenic targets.
• • siRNA-mediated LINC00114 knockdown (si-LINC00114) reduces CRC cell proliferation and metastasis by >50% and downregulates HNRNPA1 expression, demonstrating a direct regulatory axis that could be exploited to inhibit tumor dissemination.
• • Exogenous glutamine supplementation (2 mM) increases LINC00114 and HNRNPA1 levels in CRC cells and promotes HUVEC tubule formation more effectively than glucose (25 mM), highlighting glutamine as a dominant metabolic fuel driving angiogenesis in CRC.
• • In vivo LINC00114 intervention represses tumor progression and vascular normalization, with reduced glutamine metabolism, suggesting that targeting this lncRNA could disrupt the metabolic and angiogenic support required for CRC growth and metastasis.